Literature DB >> 14724297

"Me-too" products--friend or foe?

Thomas H Lee1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14724297     DOI： 10.1056/NEJMp038215

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

1.  Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry.

Authors:  Hamid Reza Poorhoseini; Seyed Ebrahim Kassaian; Kianoosh Hoseini; Sepideh Saroukhani; Mojtaba Salarifar; Mohammad Alidoosti; Ebrahim Nematipour; Ali Mohammad Haji-Zeinali; Alireza Amirzadegan; Mir Hossein Seyyed Mohammadzadeh; Kamal Khadem Vatan; Hassan Aghajani; Mahmood Sheikh Fathollahi; Hamidreza Farrokh-Eslamlou
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-02-07

2.  The economics of follow-on drug research and development: trends in entry rates and the timing of development.

Authors:  Joseph A DiMasi; Cherie Paquette
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  No cure, no pay.

Authors:  Claus Møldrup
Journal:  BMJ       Date:  2005-05-28

4.  Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices.

Authors:  Joel Lexchin
Journal:  CMAJ       Date:  2006-04-11       Impact factor: 8.262

5.  Patent nonsense: evidence tells of an industry out of social control.

Authors:  Henry Mintzberg
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

6.  [Clinical drug therapy].

Authors:  Markus Müller
Journal:  Wien Med Wochenschr       Date:  2006-09

7.  Doctors' attitudes about prescribing and knowledge of the costs of common medications.

Authors:  C McGuire; S King; G Roche-Nagle; M C Barry
Journal:  Ir J Med Sci       Date:  2009-02-17       Impact factor: 1.568

8.  'Me-Too' Innovation in Pharmaceutical Markets.

Authors:  Anupam B Jena; John E Calfee; Edward C Mansley; Tomas J Philipson
Journal:  Forum Health Econ Policy       Date:  2009-11-04

Review 9.  ["Me-too drugs" and the concept of a class effect].

Authors:  Brigitte Blöchl-Daum
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 10.  Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

Authors:  Erik Serrao; Srinivas Odde; Kavya Ramkumar; Nouri Neamati
Journal:  Retrovirology       Date:  2009-03-05       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.